RTTNews | Dec 16, 2020 04:35AM EST

04:35 Wednesday, December 16, 2020 (RTTNews.com) - Daiichi Sankyo Europe GmbH (DSKYF.PK) and Esperion Therapeutics (ESPR) announced Swissmedic approval for NILEMDO tablet and NUSTENDI tablet, for people with high low-density lipoprotein cholesterol in Switzerland. NILEMDO (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients.

Lucas Schalch, Country Manager at Daiichi Sankyo Switzerland, said: "Today's approval of NILEMDO and NUSTENDI is a pivotal milestone for patients in secondary prevention, offering them new, convenient treatment options and demonstrating another step forward in our commitment to reduce the risk of atherosclerotic cardiovascular disease."

Read the original article on RTTNews ( https://www.rttnews.com/3154097/daiichi-sankyo-esperion-report-swissmedic-approval-for-nilemdo-nustendi.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved